These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21396745)

  • 1. Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors.
    Yao Z; Wei X; Wu X; Katz JL; Kopajtic T; Greig NH; Sun H
    Eur J Med Chem; 2011 May; 46(5):1841-8. PubMed ID: 21396745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 9-Cyclopropylmethoxy-dihydrotetrabenazine and its stereoisomers as vesicular monoamine transporter-2 inhibitors.
    Wang W; Lin S; Du G; Bai X; Lu J; Ye L; Wang H; Zhang R; Tian J
    Future Med Chem; 2022 Jul; 14(13):991-1003. PubMed ID: 35638444
    [No Abstract]   [Full Text] [Related]  

  • 3. Synthesis and evaluation of 2-amino-dihydrotetrabenzine derivatives as probes for imaging vesicular monoamine transporter-2.
    Zhu L; Liu J; Kung HF
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5026-8. PubMed ID: 19632829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of 3-alkyl-dihydrotetrabenazine derivatives as vesicular monoamine transporter-2 (VMAT2) ligands.
    Zheng P; Lieberman BP; Choi SR; Plöessl K; Kung HF
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3435-8. PubMed ID: 21531556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.
    Koch J; Shi WX; Dashtipour K
    Pharmacol Ther; 2020 Aug; 212():107580. PubMed ID: 32454050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors.
    Yang Y; Yu D; Zhu X; Du G; Wang W; Zou F; Wang H; Zhang R; Ye L; Tian J
    Eur J Med Chem; 2021 Nov; 224():113718. PubMed ID: 34329999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deutetrabenazine for the treatment of Huntington's chorea.
    Bashir H; Jankovic J
    Expert Rev Neurother; 2018 Aug; 18(8):625-631. PubMed ID: 29996061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific.
    Kilbourn M; Lee L; Vander Borght T; Jewett D; Frey K
    Eur J Pharmacol; 1995 May; 278(3):249-52. PubMed ID: 7589162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrrolidine analogs of GZ-793A: synthesis and evaluation as inhibitors of the vesicular monoamine transporter-2 (VMAT2).
    Penthala NR; Ponugoti PR; Nickell JR; Deaciuc AG; Dwoskin LP; Crooks PA
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3342-5. PubMed ID: 23597792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absolute configuration of (+)-alpha-dihydrotetrabenazine, an active metabolite of tetrabenazine.
    Kilbourn MR; Lee LC; Heeg MJ; Jewett DM
    Chirality; 1997; 9(1):59-62. PubMed ID: 9094204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.
    Meyer AC; Horton DB; Neugebauer NM; Wooters TE; Nickell JR; Dwoskin LP; Bardo MT
    Neuropharmacology; 2011 Sep; 61(4):849-56. PubMed ID: 21669212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites.
    Grigoriadis DE; Smith E; Hoare SRJ; Madan A; Bozigian H
    J Pharmacol Exp Ther; 2017 Jun; 361(3):454-461. PubMed ID: 28404690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
    Peckham AM; Nicewonder JA
    J Pharm Pract; 2019 Aug; 32(4):450-457. PubMed ID: 29455579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.
    Ugolev Y; Segal T; Yaffe D; Gros Y; Schuldiner S
    J Biol Chem; 2013 Nov; 288(45):32160-32171. PubMed ID: 24062308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
    Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF
    Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (+)-9-Benzyloxy-α-dihydrotetrabenazine as an important intermediate for the VMAT2 imaging agents: absolute configuration and chiral recognition.
    Liu C; Chen Z; Li X; Tang J; Qin X
    Chirality; 2013 Apr; 25(4):215-23. PubMed ID: 23532997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A concise total synthesis of (+)-tetrabenazine and (+)-α-dihydrotetrabenazine.
    Paek SM; Kim NJ; Shin D; Jung JK; Jung JW; Chang DJ; Moon H; Suh YG
    Chemistry; 2010 Apr; 16(15):4623-8. PubMed ID: 20235241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VMAT2 Inhibitors in Neuropsychiatric Disorders.
    Tarakad A; Jimenez-Shahed J
    CNS Drugs; 2018 Dec; 32(12):1131-1144. PubMed ID: 30306450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Experience With VMAT2 Inhibitors.
    Niemann N; Jankovic J
    Clin Neuropharmacol; 2019; 42(2):37-41. PubMed ID: 30870235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N; Jankovic J
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.